Genpact (G) Competitors $44.30 -1.00 (-2.21%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$44.82 +0.52 (+1.17%) As of 07/11/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock G vs. CCRN, BR, GPN, JKHY, EXLS, WEX, EEFT, MMS, PAY, and WUShould you be buying Genpact stock or one of its competitors? The main competitors of Genpact include Cross Country Healthcare (CCRN), Broadridge Financial Solutions (BR), Global Payments (GPN), Jack Henry & Associates (JKHY), ExlService (EXLS), WEX (WEX), Euronet Worldwide (EEFT), Maximus (MMS), Paymentus (PAY), and Western Union (WU). Genpact vs. Its Competitors Cross Country Healthcare Broadridge Financial Solutions Global Payments Jack Henry & Associates ExlService WEX Euronet Worldwide Maximus Paymentus Western Union Genpact (NYSE:G) and Cross Country Healthcare (NASDAQ:CCRN) are related companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Is G or CCRN more profitable? Genpact has a net margin of 10.88% compared to Cross Country Healthcare's net margin of -1.41%. Genpact's return on equity of 22.35% beat Cross Country Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets Genpact10.88% 22.35% 10.50% Cross Country Healthcare -1.41%2.56%1.84% Does the media prefer G or CCRN? In the previous week, Genpact had 13 more articles in the media than Cross Country Healthcare. MarketBeat recorded 15 mentions for Genpact and 2 mentions for Cross Country Healthcare. Cross Country Healthcare's average media sentiment score of 0.85 beat Genpact's score of 0.63 indicating that Cross Country Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genpact 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Cross Country Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, G or CCRN? Genpact has higher revenue and earnings than Cross Country Healthcare. Cross Country Healthcare is trading at a lower price-to-earnings ratio than Genpact, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenpact$4.77B1.63$513.67M$2.9315.12Cross Country Healthcare$1.34B0.29-$14.56M-$0.53-22.77 Do institutionals & insiders believe in G or CCRN? 96.0% of Genpact shares are owned by institutional investors. Comparatively, 96.0% of Cross Country Healthcare shares are owned by institutional investors. 3.1% of Genpact shares are owned by company insiders. Comparatively, 4.9% of Cross Country Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer G or CCRN? Genpact presently has a consensus target price of $50.14, indicating a potential upside of 13.19%. Cross Country Healthcare has a consensus target price of $17.93, indicating a potential upside of 48.55%. Given Cross Country Healthcare's higher possible upside, analysts clearly believe Cross Country Healthcare is more favorable than Genpact.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genpact 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43Cross Country Healthcare 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, G or CCRN? Genpact has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Cross Country Healthcare has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. SummaryGenpact beats Cross Country Healthcare on 12 of the 15 factors compared between the two stocks. Get Genpact News Delivered to You Automatically Sign up to receive the latest news and ratings for G and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding G and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart G vs. The Competition Export to ExcelMetricGenpactIT Services IndustryComputer SectorNYSE ExchangeMarket Cap$7.75B$16.57B$27.54B$20.60BDividend Yield1.53%1.51%3.12%3.72%P/E Ratio15.1238.8036.9327.81Price / Sales1.6311.861,858.7140.76Price / Cash12.3124.5737.5522.32Price / Book3.274.877.284.57Net Income$513.67M$434.10M$767.99M$989.30M7 Day Performance-3.53%-5.91%-0.26%0.20%1 Month Performance3.26%0.40%6.06%5.53%1 Year Performance36.52%14.56%52,479.79%10.30% Genpact Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GGenpact3.8376 of 5 stars$44.30-2.2%$50.14+13.2%+36.5%$7.75B$4.77B15.12140,000Dividend AnnouncementCCRNCross Country Healthcare3.9112 of 5 stars$12.75-2.0%$17.93+40.6%-12.5%$417.95M$1.34B-24.068,205Positive NewsBRBroadridge Financial Solutions4.2174 of 5 stars$240.32-0.7%$250.83+4.4%+14.4%$28.23B$6.51B36.1414,600Positive NewsGPNGlobal Payments4.994 of 5 stars$80.03-2.2%$110.91+38.6%-19.1%$19.52B$10.11B12.9127,000News CoveragePositive NewsAnalyst ForecastJKHYJack Henry & Associates3.8181 of 5 stars$180.52-0.4%$185.11+2.5%+5.4%$13.15B$2.22B30.757,170News CoverageAnalyst UpgradeEXLSExlService4.7381 of 5 stars$45.19-0.2%$51.50+14.0%+27.8%$7.35B$1.84B34.2359,500Positive NewsHigh Trading VolumeWEXWEX4.462 of 5 stars$149.51-1.1%$176.90+18.3%-17.7%$5.12B$2.63B19.276,500Trending NewsEEFTEuronet Worldwide4.2271 of 5 stars$106.00-0.5%$126.86+19.7%-0.5%$4.58B$4.05B15.7010,600News CoveragePositive NewsUpcoming EarningsMMSMaximus3.7521 of 5 stars$71.29-1.1%$90.00+26.2%-18.4%$4.02B$5.31B14.1741,100News CoverageDividend AnnouncementPAYPaymentus4.11 of 5 stars$30.86-0.6%$36.80+19.2%+45.7%$3.86B$871.74M79.131,307High Trading VolumeWUWestern Union4.9407 of 5 stars$8.53-1.0%$10.78+26.4%-33.5%$2.82B$4.21B3.189,100 Related Companies and Tools Related Companies Cross Country Healthcare Competitors Broadridge Financial Solutions Competitors Global Payments Competitors Jack Henry & Associates Competitors ExlService Competitors WEX Competitors Euronet Worldwide Competitors Maximus Competitors Paymentus Competitors Western Union Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:G) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genpact Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Genpact With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
